Dialysis; Complications
Conditions
Brief summary
Thyroid dysfunction is a prevalent endocrine disorder that significantly impacts the health of patients with chronic kidney disease (CKD), particularly those undergoing dialysis. The prevalence of thyroid dysfunction in dialysis patients has been reported to range from 20% to 60%, highlighting the need for routine screening and management in this vulnerable group (Kuo et al., 2024). Thyroid hormones play a crucial role in regulating various physiological processes, and their dysregulation can lead to complications such as cardiovascular disease, anemia, and impaired quality of life, which are particularly concerning in the dialysis population (Smith et al., 2024). The relationship between CKD and thyroid dysfunction is complex and multifactorial. Uremic toxins can interfere with the hypothalamic-pituitary-thyroid axis, leading to alterations in thyroid hormone production and metabolism. Recent studies have shown that inflammation and oxidative stress associated with CKD can further exacerbate thyroid dysfunction (Johnson et al., 2024). Understanding these mechanisms is essential for developing effective management strategies for thyroid health in dialysis patients.
Interventions
DIAGNOSTIC_TESTThyroid profile
Thyroid dysfunction in patients undergoing hemogdialysis in sohag university hospital
Sponsors
Sohag University
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
13 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
* Adults aged 18 years and older. * Patients diagnosed with end-stage renal disease (ESRD) on regular hemodialysis for at least 3 months.
Exclusion criteria
* Known Thyroid Disorders: Patients with a history of thyroid disease (e.g., hypothyroidism, hyperthyroidism) prior to starting dialysis. * Recent Thyroid Treatment: Patients who have received treatment for thyroid dysfunction (e.g., thyroid hormone replacement, antithyroid medications) within the last six months. * Patients with acute kidney injury (AKI) or those who are not on regular dialysis. * Pregnant or lactating women. * Patients with systemic illnesses or medications that could interfere with thyroid function tests (e.g., corticosteroids, lithium).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Thyroid Dysfunction Diagnosed by Serum TSH, Free T3, and Free T4 Levels | Up to 6 months from enrollment | Diagnosis will be classified as: Hypothyroidism Subclinical hypothyroidism Hyperthyroidism |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Thyroid Dysfunction Stratified by Dialysis Duration and Ultrafiltration Rate | Up to 6 months from enrollment | Number of Participants With Thyroid Dysfunction Stratified by Dialysis Duration and Ultrafiltration Rate Dialysis duration recorded in months Ultrafiltration rate recorded in mL/kg/hour Thyroid dysfunction diagnosed by TSH, free T3, and free T4 levels |
Other
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Thyroid Dysfunction by Underlying Cause of Kidney Disease | Up to 6 months from enrollment | Number of Participants With Thyroid Dysfunction by Underlying Cause of Kidney Disease Kidney disease categories: Diabetic nephropathy Hypertensive nephrosclerosis Chronic glomerulonephritis Thyroid dysfunction diagnosed by serum TSH, free T3, and free T4 |
Countries
Egypt
Outcome results
None listed